Rapid Diagnosis of Bacterial Meningitis with Vivalytic
Rapid Diagnosis of Bacterial Meningitis with Vivalytic
Rapid Diagnosis of Bacterial Meningitis with Vivalytic
Randox Laboratories, in collaboration with Bosch Healthcare Solutions (BHCS) is proud to announce the availability of the new Vivalytic Bacterial Meningitis panel on the Vivalytic platform. This highly advanced multiplex PCR test detects six of the most common bacterial pathogens responsible for meningitis, providing results in under an hour.
Meningitis is a critical medical emergency that requires rapid diagnosis to ensure timely and targeted treatment according to current guidelines (1). Over 2,5 million people are infected globally by meningitis each year, with half of these cases affecting children below the age of 5 (2). Furthermore, 20% of bacterial meningitis cases lead to permanent complications such as hearing loss, seizures or brain damage(3), if immediate treatment is not received, about 50% of cases will be fatal (4).
Enter Vivalytic
With a sample of only 200μl of cerebral spinal fluid (CSF), the Vivalytic Bacterial Meningitis Panel simplifies and accelerates the diagnostic process into 4 simple steps, delivering reliable results within 1 hour to support life-saving clinical decisions with the appropriate antibiotic treatment.
The panel detects key pathogens associated with bacterial meningitis:
| Detectable Pathogens | |
|---|---|
| Escherichia coli K1 | Neisseria meningitidis |
| Haemophilus influenzae | Streptococcus agalactiae |
| Listeria monocytogenes | Streptococcus pneumoniae |
The innovative all-in-one Vivalytic cartridge minimises the risk of contamination and reduces hands-on time for laboratory staff. This new panel aligns with our mission to improve patient outcomes and support healthcare providers with cutting-edge diagnostic solutions.
The Vivalytic Bacterial Meningitis panel is CE-marked and available to order. For further information on rapid diagnosis of bacterial meningitis with Vivalytic, please visit https://www.randox.com/vivalytic-bacterial-meningitis/ or contact your Randox representative.
References
- Pfister H.-W., Klein M. et al., Ambulant erworbene bakterielle Meningoenzephalitis im Erwachsenenalter, S2k-Leitlinie, 2023, in: Deutsche Gesellschaft für Neurologie (Ed.), Leitlinien für Diagnostik und Therapie in der Neurologie. https://dgn.org/leitlinie/ambulant-erworbene-bakterielle-meningoenzephalitis-im-erwachsenenalter
- GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2023 Aug;22(8):685-711
- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. Erratum in: Lancet. 2020 Nov 14;396(10262):1562. https://pubmed.ncbi.nlm.nih.gov/33069326/ (retrieved on 12/17/2024)
- https://www.who.int/news-room/fact-sheets/detail/meningitis (retrieved on 12/17/2024)